Brain power

unleashed
Transforming health
and human capacity
APPLY NOW

The very First

Non-surgical Bidirectional BCI

Nanoparticles designed for the stimulation and recording of neural activity from within the brain

MISSION

Subsense aims to unlock limitless human potential by creating safe, effective, and accessible brain-computer interfaces that elevate lives and redefine the interaction between human cognition and technology

VISION

Subsense envisions a future where the synergy between human cognition and technology expands our capabilities beyond current limitations, enabling seamless communication, enhanced cognitive functions and transformative medical treatments

POTENTIAL IMPACT

Brain-computer interfaces hold the promise of transforming lives for the better. Our aim is to transition this technology from research environments to everyday use.

who
it's for

Our brain-computer interface is a game-changer for those with paralysis and neurological disorders. It transforms thoughts into digital control, offering new independence by simplifying everyday interactions and enhancing treatment.

who it's for

Our brain-computer interface is a game-changer for those with paralysis and neurological disorders. It transforms thoughts into digital control, offering new independence by simplifying everyday interactions and enhancing treatment.

Potential application
and vision

Treating
Our BCI brings a revolutionary approach to treating neurological and neurodegenerative diseases through targeted stimulation of specific brain regions. This technology holds promise for restoring motor functions and enhancing rehabilitation therapies, offering a new chapter of hope and progress in neurological treatment
Human-machine interaction
In the future, humans and machines will seamlessly connect, and our BCI technology will be the bridge. It has the potential to revolutionize how we interact with our digital world, from controlling computers and smartphones to navigating complex machinery. This not only enhances accessibility for those with physical limitations but also opens new frontiers in how we all experience technology in our everyday lives
Diagnostics
Our technology offers a new dimension of insight. It enables real-time monitoring of brain activity, providing critical data that can aid in the early detection and understanding of neurological conditions. This could lead to more accurate diagnoses, better-informed treatment plans, and a deeper understanding of brain health
Biocompatible nanoparticles
Our biocompatible nanoparticles represent the forefront of innovation in BCI technology. Engineered to seamlessly integrate with the human brain, these nanoparticles are designed for safety and compatibility. They form the core of our BCI system, capable of accurately recording and stimulating brain activity without adverse effects, paving the way for safer, more effective neurological treatments and interfaces
Non-invasive technology
At the heart of our approach is a commitment to non-invasive technology. Our system is designed to interact with the brain without the need for surgical implants, ensuring a safer and more comfortable experience for users. This approach not only reduces risks associated with invasive procedures but also makes our technology more accessible to a wider range of individuals
Hardware
Our hardware is crafted with precision to ensure optimal signal capture and transmission from the nanoparticles, designed to bridge the gap between the brain and digital world seamlessly

Advantages over other methods

BCI on Nanoparticles
Invasive / Semi-invasive BCI
Non-invasive BCI (EEG)
External device (TMS, MEG, MRI)
Regular pharma
Applications
Disease treatment, restore function, neuronal activity monitoring, precise drug delivery
Disease treatment, restore function
Restore function, neuronal activity monitoring, motor imagery, biofeedback
Local brain stimulation, magnetic field recording
Disease treatment, drug delivery
Non-surgical
Intravenous / intranasal / oral
Connection with deep brain structures
Recording of neural activity
Wireless control
Restore function (physical / chemical)
Drug delivery
BCI on Nanoparticles
Disease treatment, restore function, neuronal activity monitoring, precise drug delivery
+ Non-surgical
+ Intravenous / intranasal / oral
+ Connection with deep brain structures
+ Recording of neural activity
+ Wireless control
+ Restore function
+ Drug delivery
Invasive / Semi-invasive BCI
Disease treatment, restore function
- Non-surgical
- Intravenous / intranasal / oral
+ Connection with deep brain structures
+ Recording of neural activity
+ Wireless control
+ Restore function
- Drug delivery
Non-invasive BCI (EEG)
Restore function, neuronal activity monitoring, motor imagery, biofeedback
+ Non-surgical
- Intravenous / intranasal / oral
- Connection with deep brain structures
+ Recording of neural activity
+ Wireless control
+ Restore function
- Drug delivery
External device (TMS, MEG, MRI)
Local brain stimulation, magnetic field recording
+ Non-surgical
- Intravenous / intranasal / oral
- Connection with deep brain structures
+ Recording of neural activity
+ Wireless control
- Restore function
- Drug delivery
Regular Pharma
Disease treatment, drug delivery
+ Non-surgical
+ Intravenous / intranasal / oral
- Connection with deep brain structures
- Recording of neural activity
- Wireless control
+ Restore function
+ Drug delivery

Team

Developing our cutting-edge product demands extensive interdisciplinary expertise. To achieve this, we have assembled a team of the finest minds in neurotechnology, nanotechnology, biology, physics, and chemistry
Tetiana Aleksandrova
CEO & co-founder

7Y leading Brain Computer Interface startups • 14Y in management • MBA • Top 100 Women in Tech • Top 100 Startups

Scott Meek
Scott Meek
Head of R&D

11Y leading startup biosensor product development • 11Y in nanomaterials research • Ph.D. in Chemistry from MIT

Alexandra Karpman
Alexandra Karpman
Head of Product

12Y in Brain-Computer Interface R&D • 6Y in Management of biomedical products • Master’s degree in Neuroscience

Uri Magaram
Uri Magaram
Experimental Applications Specialist

9 years neuroscience tool development • 13 years neuroscience labs • Ph.D. in Neurosciences from UCSD

Cyril Eleftheriou
Cyril Eleftheriou
Neurotech Lead

17 years in neuro-engineering • 12 years of neuro-prosthetics research • Ph.D. in Neuroscience from Newcastle University

Anthony Di Pasqua
Anthony Di Pasqua
Nanoscience Lead

20 years in nanomaterials • 15 years in preclinical research • Ph.D. in Chemistry from Syracuse University

Samantha Isabelle K. Portea
Samantha Isabelle K. Portea
Laboratory Manager

8Y in lab operations across biotech, academia & diagnostics • B.S. in Microbiology from UC Davis

Aleksandra Isaenko
Aleksandra Isaenko
Operational Manager

13Y in Startups experience as Finance & Integrations manager • 20Y in management • Finance degree • IFA GB

Valeriya Santos
Valeriya Santos
Administrative Executive

10+ years in the field of Hospitality and foreign languages • Master in Hospitality and International Tourism

Katsiaryna Tsiukhai
Katsiaryna Tsiukhai
Invited UX/UI designer

10Y in UX/UI & Product Design • Co-founder Sizze.io & Capsula.mx • Red Dot Award Winner

Advisors

Prof. Dr. Bradley Nelson
Prof. Dr. Bradley Nelson

Professor of Robotics and Intelligent Systems at ETH Zürich • Department Head of Mechanical and Process Engineering at ETH • Chairman of the ETH Electron Microscopy Center • Member of the Research Council of the Swiss National Science Foundation • Co-​Director of the Multi-Scale Robotics Lab, ETH Zürich

Prof. Salvador Pané i Vidal
Prof. Salvador Pané i Vidal

Professor of Materials for Robotics at the Institute of Robotics and Intelligent Systems (IRIS) • Co-​Director of the Multi-​Scale Robotics Lab at ETH Zürich

Prof. Valeria Chiono
Prof. Valeria Chiono

Full Professor at the Department of Mechanical and Aerospace Engineering (DIMEAS), Politecnico di Torino • Member of Interdepartmental Center PolitoBIOMed Lab – Biomedical Engineering Lab • Substitute member Comitato Etico per la Ricerca

Prof. Ajeet Kaushik
Prof. Ajeet Kaushik

Assistant Professor, Chemistry • NanoBioTech Laboratory, Health System Engineering, Departmental of Environmental Engineering, Florida Polytechnic University, Lakeland, FL-USA

roadmap

News

2025 Winners - MedTech Breakthrough
May 08, 2025

2025 Winners – MedTech Breakthrough
The Promise and Challenges of Brain–Computer Interfaces
March 17, 2025

The Promise and Challenges of Brain–Computer Interfaces
February 27, 2025

Pinnacle Award Winners 2025 Healthcare
Press Release subsense
February 18, 2025

Press Release

Subsense is thrilled to announce our emergence from stealth with a $17M seed round led by Golden Falcon Capital. We are pioneering the first non-surgical, nanoparticle-based BCI, transforming neurotechnology

Media coverage

Subsense Develops Nonsurgical, Nanoparticle-Based Computer Interface For Neurological Disorders
May 05, 2025

Subsense Develops Nonsurgical, Nanoparticle-Based Computer Interface For Neurological Disorders
We want to completely change interaction with the digital world
April 11, 2025

'We want to completely change interaction with the digital world'
The Prototype: This Startup Is Building Nanoparticles To Connect Brains To Computers
April 04, 2025

The Prototype: This Startup Is Building Nanoparticles To Connect Brains To Computers
Biocompatible Nanoparticles: Tiny Antennae with Huge Potential for Brain-Computer Interfaces
February 28, 2025

Biocompatible Nanoparticles: Tiny Antennae with Huge Potential for Brain-Computer Interfaces
Subsense gets $17M to develop brain-computer interface
February 25, 2025

Subsense gets $17M to develop brain-computer interface
Subsense emerges from stealth with $17m for nanoparticle BCI development
February 19, 2025

Subsense emerges from stealth with $17m for nanoparticle BCI development
Subsense emerges with nanoparticle-based brain-computer interface
February 19, 2025

Subsense emerges with nanoparticle-based brain-computer interface
Subsense emerges from stealth with $17m for nanoparticle BCI development
February 19, 2025

Subsense emerges from stealth with $17m for nanoparticle BCI development
Exclusive: Subsense launches with $17M to build a noninvasive brain computer interface
February 18, 2025

Exclusive: Subsense launches with $17M to build a noninvasive brain computer interface
Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface
February 18, 2025

Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface
BCI maker Subsense emerges from stealth
February 18, 2025

BCI maker Subsense emerges from stealth
June 30, 2025

The Next Great Bitcoin Investment
June 04, 2025

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap
Apple Adds Brain-to-Computer Protocol to Its Accessibility Repertoire
May 14, 2025

Apple Adds Brain-to-Computer Protocol to Its Accessibility Repertoire
Execs On The Move: 21-25 April 2025
May 07, 2025

Execs On The Move: 21-25 April 2025
AI Biotech Creyon in Deal With Lilly That Could Yield Mega Payoff
May 01, 2025

AI Biotech Creyon in Deal With Lilly That Could Yield Mega Payoff
Nanoparticle BCIs: Fact or Fiction
April 01, 2025

Nanoparticle BCIs: Fact or Fiction
Neurotech Notables: Subsense launches with $17M to build a noninvasive brain computer interface
March 28, 2025

Neurotech Notables: Subsense launches with $17M to build a noninvasive brain computer interface
Subsense Attracts $17 Million in Seed Funding
March 07, 2025

Subsense Attracts $17 Million in Seed Funding

Subsense: $17 Million (Seed) Secured For Non-Surgical Brain-Computer Interface
March 03, 2025

Subsense: $17 Million (Seed) Secured For Non-Surgical Brain-Computer Interface
Follow the Money: Subsense raises $17M in seed funding for non-surgical BCI
February 28, 2025

Follow the Money: Subsense raises $17M in seed funding for non-surgical BCI
February 26, 2025

Subsense raises $17M in seed funding from Golden Falcon Capital
February 26, 2025

Follow the Money: Subsense raises $17M in seed funding
Subsense: $17 Million (Seed) Secured For A Non-Surgical Brain-Computer Interface
February 25, 2025

Subsense: $17 Million (Seed) Secured For A Non-Surgical Brain-Computer Interface
WSJ Pro VC: Subsense raises $17M in seed funding for non-invasive BCI
February 20, 2025

WSJ Pro VC: Subsense raises $17M in seed funding for non-invasive BCI
Subsense emerges from stealth with $17M in funding for non-invasive BCI
February 20, 2025

Subsense emerges from stealth with $17M in funding for non-invasive BCI
Axios Pro Rata: Subsense raises $17M in seed funding
February 19, 2025

Axios Pro Rata: Subsense raises $17M in seed funding
Fortune Term Sheet: Subsense raises $17M in seed funding
February 19, 2025

Fortune Term Sheet: Subsense raises $17M in seed funding
Subsense Emerges from Stealth with $17M in Seed Funding for a Non-Surgical Brain-Computer Interface
February 19, 2025

Subsense Emerges from Stealth with $17M in Seed Funding for a Non-Surgical Brain-Computer Interface
Subsense launches with $17M to build nanoparticle-based brain-computer interface
February 19, 2025

Subsense launches with $17M to build nanoparticle-based brain-computer interface
Subsense Emerges From Stealth With $17 Million
February 19, 2025

Subsense Emerges From Stealth With $17 Million
Subsense Unveils $17M Seed Funding for Non-Surgical Brain-Computer Interface Development
February 19, 2025

Subsense Unveils $17M Seed Funding for Non-Surgical Brain-Computer Interface Development
Health Tech Deals: Subsense raises $17M in stealth funding
February 18, 2025

Health Tech Deals: Subsense raises $17M in stealth funding
Financings for Feb. 18, 2025
February 18, 2025

Financings for Feb. 18, 2025
Subsense Emerges With $17M Seed Funding
February 18, 2025

Subsense Emerges With $17M Seed Funding
Subsense Emerges With $17M Seed Funding
February 18, 2025

Subsense Raises $17M in Seed Funding

careers

Partners

apply now

Max file size 10MB.
© Subsense 2024-2025
Subsense products are not authorized, cleared, or approved by the FDA for marketing in the US Performance claims have not yet been evaluated by the FDA.